On the basis of these results, in May 2018 crizotinib received breakthrough therapy designation from the United States Food and Drug Administration (US FDA), for the treatment of metastatic NSCLC in patients with MET exon 14 skipping alterations and progression on or after platinum-based chemotherapy (Drilon et al., 2016; Pfizer, 2020). The gene discussed is MET; the disease is non-small cell lung carcinoma.